Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates

Authors: Tom Scheidt, Urszula Łapińska, Janet R. Kumita, Daniel R. Whiten, David Klenerman, Mark R. Wilson, Samuel I. A. Cohen, Sara Linse, Michele Vendruscolo, Christopher M. Dobson, Tuomas P. J. Knowles, and Paolo Arosio

Science Advances, 2019, 5, eaau3112. DOI: 10.1126/sciadv.aau3112 



The aggregates of the Aβ peptide associated with Alzheimer’s disease are able to both grow in size as well as generate, through secondary nucleation, new small oligomeric species, that are major cytotoxins associated with neuronal death. Despite the importance of these amyloid fibril-dependent processes, their structural and molecular underpinnings have remained challenging to elucidate. Scheidt et al., they consider two molecular chaperones: the Brichos domain, which suppresses specifically secondary nucleation processes, and clusterin which their results show is capable of inhibiting, specifically, the elongation of Aβ fibrils at remarkably low substoichiometric ratios.

Microfluidic diffusional sizing measurements demonstrate that this inhibition originates from interactions of clusterin with fibril ends with high affinity. Kinetic experiments in the presence of both molecular chaperones reveal that their inhibitory effects are additive and noncooperative, thereby indicating that the reactive sites associated with the formation of new aggregates and the growth of existing aggregates are distinct.

Read the full paper


Therapeutic area: amyloid, neurodegeneration, protein-protein interactions

Fluidic Analytics is changing how proteins are characterised

We're doing this with novel, cutting edge technology and a fantastic, committed team

Find out more